Significance and implication of the changes of serum interlukin-11 level in patients with hematological malignancy post-chemotherapy
10.3760/cma.j.issn.1009-9921.2009.05.011
- VernacularTitle:血液肿瘤化疗后血清可溶性白细胞介素-11水平的变化及其意义
- Author:
Kaitai WANG
;
Hongjuan LU
;
Tianshu WANG
;
Jun SHEN
;
Haiyan YUAN
;
Lili ZHOU
;
Xiaofen YANG
- Publication Type:Journal Article
- Keywords:
Hematologic neoplasms;
Interleukin-11;
Thrombocytopenia
- From:
Journal of Leukemia & Lymphoma
2009;18(5):287-289
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the relationship between plasma interleukin-11(sIL-11) level and platelet count post-chemotherapy with hematological malignancy patients and analyse a sIL-11 level which may maintain a safe platelet count so as to guide the treatment. Methods Blood samples were collected from the patients with hematological malignancy at certain time point of pre-and post-chemotherapy, and serum level of sIL-11 and platelet count were determined separately. Different statistical methods were applied to test the relationship between sIL-11 level and platelet changes. Results 99 cases finished this study. The findings are: the sIL-11 level went up and reached the peak on day 6 post-chemotherapy, while the platelet count kept dropping to the lowest on day 10, the sIL-11 peak occurred before the lowest platelet count, patients with faster sIL-11 increase may maintain a comparatively higher plateled count. 99 eases were grouped according to the lowest platelet count and compared: the group with higher platelet count tend to have higher peak sIL-11, more cases with higher peak sIL-11, with faster daily average sIL-11 increase, the lowest platelet count occurred later. Logistic regression analysis showed the factors contributed to lower platelet includes slower daily average sIL-11 increase and sIL-11 level less than 2000 pg/ml on Day4 post-chemotherapy. Conclusion There were correlation between the serum sIL-11 level and platelet counts, the platelet count change may be predicted by determining the plasma sIL-11 level post-chemotherapy. Patients with sIL-11 level less than 2000 pg/ml on Day4 post-chemotherapy may be endangered with severe thrombocytopenia, rhIL-11 or platelet transfusion treatment should be considered.
